BioSpace News Archive

ASGCT’s “Advancing Cell and Gene Therapies for Cancer” is a 1.5 day conference taking place October 15-16, 2025, at the Philadelphia Marriott Downtown, focusing on the latest research in cell and gene therapies for cancer treatment. Attendees will explore cutting-edge advancements in oncolytic viruses, cell and immunotherapies, and combination approaches designed to improve patient outcomes while tackling critical challenges like tumor heterogeneity and delivery limitations.

In coordination with the United States President’s Emergency Plan for AIDS Relief, Gilead will make its twice-yearly HIV prophylactic Yeztugo available to resource-limited countries “at no profit.”

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to Dupixent, according to analysts at Leerink Partners.

Ousted CDC Director Susan Monarez claimed in an op-ed published in The Wall Street Journal Thursday that she was fired for refusing to rubber-stamp COVID-19 recommendations to be made by an advisory panel that has expressed “antivaccine rhetoric.”

Hengrui Pharmaceuticals has been busy this year, signing a nearly $2 billion cardio contract with Merck in March and a 12-asset agreement with GSK in July worth up to $12 billion.

Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies, which founded Lykos, bemoaned a “moving of the goal posts” in Lykos’ rejection but looked for positives in the newly released complete response letter.

Robert F. Kennedy Jr. repeated a series of anti-vaccine talking points during his appearance in front of the Senate finance committee on Thursday, as Democratic and Republican senators alike hammered the Health Secretary on recent COVID-19 vaccine restrictions and his views on Operation Warp Speed.

Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.